Cytek Biosciences enters its post-earnings stretch on the back foot. Q1 EPS came in at -$0.15, missing the -$0.10 consensus by 50%, while revenue of $44.1M also fell short of estimates — and the stock gapped down 6.7% on the print.
The short interest picture has been slowly tightening over the past month, and this week's earnings miss puts that build in focus. Short interest now runs at 6.3% of the free float — up roughly 4.6% over the past 30 days and continuing to climb, with the latest reading at approximately 8.1 million shares. That is a measured rather than aggressive build; the week-on-week increase of 0.7% signals steady accumulation rather than a sharp new conviction. Availability is exceptionally loose at more than 2,100% of short interest, meaning there is no constraint on new shorts entering the name. Cost to borrow at 0.61% is barely above benchmark — borrow is essentially free. Nothing in the lending market suggests crowding or squeeze risk.
Options tell a mildly more cautious story, though not an alarming one. The put/call ratio has drifted up to 0.31 from a low base — still well below the 52-week high of 1.82, and only 0.78 standard deviations above the 20-day mean of 0.22. That reflects a modest increase in hedging activity since mid-April, when the PCR was near zero, but options traders are not pricing in severe downside. The ORTEX short score of 57.1 ranks in the 25th percentile of the short score universe — a middling signal that short pressure is present but not extreme.
The Street remains split, and the recent analyst record is worth noting with caution: the most recent changes are from early January 2026 (TD Cowen lifting its target to $5.00 while keeping a Buy) and November 2025 (Piper Sandler trimming to $7.50 on an Overweight). Goldman Sachs has maintained a Sell since early 2025, most recently with a $3.00 target — and that remains the outlier bear case. The mean price target sits at $6.00, implying roughly 30% upside to the $4.61 close, though that consensus is thin (just two hold ratings formally recorded) and many of the targets predate recent price weakness. The company reaffirmed its full-year 2026 revenue guidance of $205M–$212M on the earnings call — bracketing the $208M analyst estimate — which keeps the top-line story intact even as the EPS miss stings. EV/EBITDA at 96.5x reflects the still-lossmaking profile; the company carries a net cash position of roughly $240M, which provides a meaningful balance sheet buffer relative to a sub-$600M market cap.
Institutional ownership shows some interesting crosscurrents. BlackRock is the largest holder at 13.3% and added 625,000 shares as of its most recent filing. Millennium Management holds 5.1% and added nearly 1.9 million shares. Topline Capital Management built an almost entirely new 5.8% stake through year-end 2025. Against that, co-founder and board member Ming Yan trimmed 1.16 million shares in Q1. The insider activity from March was routine — small tax-related sales alongside RSU awards — rather than a directional signal, and the 90-day net insider position is actually slightly positive at $225,000.
Peers in life science tools had a strong week while CTKB lagged. MRVI gained 30% on the week and WAT added 15.6%. BRKR rose 20%. That sector tailwind makes CTKB's flat weekly performance — down 0.2% before Friday's post-earnings gap — look distinctly weak. TMO and DHR also underperformed the group but remained far less volatile. The next earnings event is flagged for June 10, giving investors about a month to weigh whether the guidance reaffirmation is sufficient to rebuild conviction after Thursday's miss.
See the live data behind this article on ORTEX.
Open CTKB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
